Avecho Biotechnology Limited, a biotechnology company, engages in the development and commercialization of human and animal health related products using its proprietary drug delivery system and Tocopherol Phosphate Mixture in Australia. The company operates through Production and Human Health segments. It also produces and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. In addition, the company's human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. Further, it develops feed additive products to enhance feed efficiency and the health of livestock animals. The company has a collaboration with Lambert Initiative at the University of Sydney for treatment of osteoarthritis. The company was incorporated in 1992 and is based in Clayton, Australia.

Avecho Biotechnology Ltd

Dr. Paul  Gavin BSc (Hons), Ph.D.

Avecho Biotechnology Ltd (AVE) Stock Analysis, Discussion Forum and Financial Metrics - ASX Exchange

AVE's latest dividend is 0.03 AUD on September 22, 2010

AVE Stock Discussion Forum and Message Board

News for ASX: AVE